logo-loader
viewFaron Pharmaceuticals Ltd

Faron Pharmaceuticals applies to list shares on Nasdaq First North Growth Market

This provides investors in the company’s native Finland, many of whom backed the last fundraiser, to trade shares on a local exchange

Faron Pharmaceuticals Ltd -

Faron Pharmaceuticals Oy (LON:FARN) has applied to have its shares listed on the Nasdaq First North Growth Market.

This provides investors in the company’s native Finland, many of whom backed the last fundraiser, to trade shares on a local exchange.

Pending the application approval, the stock will begin trading on December 1.

Quick facts: Faron Pharmaceuticals Ltd

Price: 238 GBX

AIM:FARN
Market: AIM
Market Cap: £103.03 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Faron Pharmaceuticals makes 'groundbreaking discovery' in its MATINS trial

Faron Pharmaceuticals Oy (LON:FARN) (FIRSTNORTH:FARON) CEO Dr Markku Jalkanen speaks to Proactive London's Andrew Scott after updating on its phase I/II MATINS trial of Clevegen. He says it's been encouraging to discover that Clevegen can ‘down’ regulate a range of checkpoints that affect the...

on 12/12/19

2 min read